Two days after the FDA revealed that it had halted enrollment in trials of respiratory syncytial virus (RSV) vaccines that ...

Shares of Moderna Inc. MRNA slipped 2.31% to $41.83 Friday, on what proved to be an all-around mixed trading session for the ...

Following news of RSV lower respiratory tract infections in infants immunized with Moderna’s investigational RNA vaccines, ...

Moderna Inc. closed $127.65 below its 52-week high ($170.47), which the company achieved on May 24th.

In the chaotic early days of the pandemic, Wall Street scrambled to place bets on the companies that looked the most likely ...

Norovirus vaccines face significant hurdles, with virtually no success from past efforts from HilleVax and Vaxxart. But ...

After several severe RSV cases were reported in a pediatric trial of Moderna's vaccine, the FDA has partially paused testing ...

If you want to stay updated on the latest options trades for Moderna, Benzinga Pro gives you real-time options trades alerts.

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 10.82% ...

Palantir, MicroStrategy, and Axon Enterprise are set to join the Nasdaq 100 Index on Monday, Dec. 23, replacing Super Micro ...

Stancik, 24, said she was "abandoned by the military" after suffering three heart attacks and a stroke after receiving the ...

FDA advisors said that more data are needed to fully understand if there are broader safety concerns related to use of ...